Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Oncology Année : 2022

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

Dates et versions

hal-04084956 , version 1 (28-04-2023)

Identifiants

Citer

Steven Tisseverasinghe, Marwan Tolba, Fred Saad, Gwenaelle Gravis, Boris Bahoric, et al.. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?. Journal of Clinical Oncology, 2022, 40 (36), pp.4173+. ⟨10.1200/JCO.22.00883⟩. ⟨hal-04084956⟩

Collections

CNRS UNIV-AMU CRCM
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More